• The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India 
• Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commercial milestone payments 

SHANGHAI, Oct. 27,...